SEARCH

SEARCH BY CITATION

References

  • 1
    Margolis HS, Alter MJ, Halder SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 8492.
  • 2
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effects of alpha-interferon treatnient in patients with Hepatitis B e antigen positive chronic Hepatitis B: a meta-analysis. Arm Intern Med 1993; 119: 312323.
  • 3
    Zoulim F, Trepo C. Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. J Hepatol 1994; 21: 142144.
  • 4
    Schalm SW, de Man RA, Heijtink RA, Niesters HGM. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995; 22(suppl 1): 5256.
  • 5
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 32′-dideoxy-32′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 84958499.
  • 6
    Tyrrell DLJ, Mitchell MC, de Man RA, Schalm SW, Main J, Thomas HC, Fevery J, et al. Phase II trial of lamivudine for chronic hepatitis B [Ab-stract]. Hepatology 1993; 18: 112A.
  • 7
    Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic viral hepatitis B infection. N Engl J Med 1995; 333: 16571661.
  • 8
    van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, et al. Evaluation of safety and efficiency of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodefi-ciency virus infection: a phase I/II study. J Infect Dis 1995; 171: 11661171.
  • 9
    Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, et al. The phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infec-tion. J Infect Dis 1995; 171: 14381447.
  • 10
    Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: have we learned from our results? Hepatology 1991; 13: 796799.
  • 11
    Lake JR. Changing indications for liver transplantation. Gastroenterol Clin North Am 1993; 22: 213229.
  • 12
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 13
    Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, et al. Rapid changes in human immunodeficiency virus type l RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171: 14111419.
  • 14
    Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA. The same mutation that encodes low-level human immunodeficiency virus type l resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37: 13901392.
  • 15
    Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron J. High-level resistance to (-) enantiomeric 2′-deoxy-3′ thia-cytidine in vitro is due to one amino acid Substitution in the catalytic site of human immunodeficiency virus type l reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 22312234.
  • 16
    Tisdale M, Kemp SD, Parry NR, Larder BS. Rapid in vitro selection of human immunodeficiency virus type l resistant to 3′-thiacytidine inhibi-tors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90: 56535656.
  • 17
    Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine ((-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine) in vitro. Antimicrob Agents Chemother 1996; 40: 19571960.
  • 18
    Seifer M, Heermann ICH, Gerlich WH. Expression pattern of the hepatitis B virus genome in transfected mouse fibroblasts. Virology 1990; 179: 287299.
  • 19
    Hilleman MR. Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different. AIDS Res Hum Retroviruses 1994; 10: 14091419.
  • 20
    Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651693.
  • 21
    Nassal M, Schaller H. Hepatitis B virus replication. Trends Microbiol 1993; 1: 221228.
  • 22
    Blum HE. Variants of hepatitis B, C and D viruses: molecular biology and clinical significance. Digestion 1995; 56: 8595.
  • 23
    Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170: 595597.
  • 24
    Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396397.
  • 25
    Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to (-) 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS related complex. AIDS 1995; 9: 351357.
  • 26
    Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8: 38673874.
  • 27
    Gutfreund KS, Fischer KP, Tipples GA, Ma M, Bain VG, Kneteman N, Tyrrell DLJ. Lamivudine results in a complete and sustained suppression of hepatitis B virus replication in patients requiring orthotopic liver transplantation for cirrhosis secondary to hepatitis B [Abstract]. Hepatology 1995; 22(suppl): 328A.